Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients

LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment

Revvity launches AI-powered software to transform preclinical imaging analysis

The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities

Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025

Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies

Aptar Pharma opens new R&D center in France

Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world

Enhertu improved in invasive disease-free survival in early breast cancer in DB-05

Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting

AbbVie submits application to FDA for Tavapadon for treatment of Parkinson's disease

If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

Cayman, Akadeum to revolutionize cell isolation for cell and gene therapy

Lilly opens biotech in San Diego

82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines